All In Biotech

Drug Trial Radar · NCT04170595

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

A Randomized, Multicenter, Phase I/IIa Clinical Study to Evaluate the Tolerability, Safety, Efficacy, Pharmacokinetics and Immunogenicity of GB221 for Injection for the Treatment of HER2-positive Breast Cancer Patients

Last checked: Nov 19, 2026Latest source record: Mar 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

132

Planned (sponsor's estimate)

Start

Mar 28, 2014

Primary completion

Dec 2021

Study completion Dec 2022

Sponsor

Lead sponsor
Genor Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, multicenter, Phase I/IIa clinical study to evaluate the tolerability, safety, efficacy, pharmacokinetics and immunogenicity after single/multiple administration of recombinant anti-HER2 humanized monoclonal antibody for injection for the treatment of HER2-positive breast cancer patients.

Conditions

  • HER2-positive Breast Cancer

Interventions

  • GB221,2 mg/kgBiological

    Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

  • GB221,6 mg/kgBiological

    Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

  • Herceptin,6 mg/kgBiological

    Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes

  • GB221,8mg/kgBiological

    Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes

  • GB221:2mg/kg and Capecitabi:1000mg/kgBiological

    GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.

  • Herceptin:2mg/kg and Capecitabin:1000mg/kgBiological

    Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. maximum tolerated dose,MTDTime frame: Up to 5 weeks
  2. C maxTime frame: Up to 5 weeks
  3. AUC (0- t)Time frame: Up to 5 weeks
  4. AUC (0- ∞ )Time frame: Up to 5 weeks
  5. T maxTime frame: Up to 5 weeks
  6. T 1/2Time frame: Up to 5 weeks
  7. CL/FTime frame: Up to 5 weeks
  8. V/FTime frame: Up to 5 weeks
  9. K eTime frame: Up to 5 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Academy of Military Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.